Previous 10 | Next 10 |
Galera Therapeutics (GRTX) +41% on updating data from pancreatic cancer trial.Willamette Valley Vineyards (WVVI) +18%.Nokia Corporation (NOK) +17% on Q1 results.VEREIT (VER) +17% as Realty Income to acquire the company.Enlivex Therapeutics (ENLV) +13%.Pluristem Therapeutics (PS...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We’re getting ready for another day of trading with a list of the top pre-market stock movers for Thursday. Today’s list has a lot of medical companies that investors will want to keep an eye on....
Enlivex Therapeutics Ltd. is a clinical-stage biopharmaceutical company aiming to develop immunotherapies as mono/combination treatments based on macrophage reprogramming technology. Enlivex's sole therapeutic is a late-stage immunotherapy, Allocetra, using early-apoptotic densel...
Enlivex Therapeutics (ENLV) announces a research collaboration with Yale Cancer Center for the assessment of the potential of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors.Allocetra is a macrophage-reprogramming immunotherapy product candidate currently ...
Nes Ziona, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, together wi...
Nes Ziona, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the following investor conferences: 2 ...
Enlivex (ENLV) announces that the Japan Patent Office issued a notice of allowance for a new patent application (number 2017-543802) covering Allocetra, the company’s immunotherapy product candidate.The company expects that this new patent will be issued in Japan in the secon...
Nes-Ziona, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced...
Enlivex Therapeutics (ENLV) has partnered with Mount Sinai Health System in a new research collaboration for the development of Allocetra with checkpoint inhibitors.Under the terms of the agreement, the two entities will develop and execute a pre-clinical program to investigate the potential ...
Enlivex Therapeutics (ENLV) and New York City's largest academic medical system Mount Sinai Health System announce a new research collaboration for the development of clinical strategies for Allocetra with checkpoint inhibitors.Allocetra is a macrophage-reprogramming immun...
News, Short Squeeze, Breakout and More Instantly...
Enlivex Therapeutics Ltd. Company Name:
ENLV Stock Symbol:
NYSE Market:
Enlivex Therapeutics Ltd. Website:
• First study of Allocetra TM in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis 1 , and has limited treatment options Nes-Ziona, Israel, July 23, 2024 (GLOB...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern T...
First patient dosed with Allocetra TM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments Ness-Ziona, Israel, June 24, 2024 (GLO...